Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katia Varani

Showing results (131-140 of 239) with videos related to

Pageof 24
Sort By:
European Journal of Medicinal Chemistry|December 7, 2015
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptorLucia Squarcialupi, Daniela Catarzi, Flavia Varano, et al.
Molecular Pharmacology|February 24, 2004
Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activationStefania Gessi, Katia Varani, Stefania Merighi, et al.
Molecular Pharmaceutics|February 2, 2012
A novel conjugated agent between dopamine and an A2A adenosine receptor antagonist as a potential anti-Parkinson multitarget approachAlessandro Dalpiaz, Barbara Cacciari, Chiara Beatrice Vicentini, et al.
Bioorganic & Medicinal Chemistry|December 30, 2011
Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonistsPier Giovanni Baraldi, Giulia Saponaro, Mojgan Aghazadeh Tabrizi, et al.
Journal of Medicinal Chemistry|January 7, 2005
Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key studyStefano Moro, Paolo Braiuca, Francesca Deflorian, et al.
Molecular Pharmacology|May 10, 2007
Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cellsStefania Merighi, Annalisa Benini, Prisco Mirandola, et al.
Plos One|June 7, 2013
Pulsed electromagnetic fields increased the anti-inflammatory effect of A₂A and A₃ adenosine receptors in human T/C-28a2 chondrocytes and hFOB 1.19 osteoblastsFabrizio Vincenzi, Martina Targa, Carmen Corciulo, et al.
Bioorganic & Medicinal Chemistry|September 3, 2003
New strategies for the synthesis of A3 adenosine receptor antagonistsPier Giovanni Baraldi, Andrea Bovero, Francesca Fruttarolo, et al.
Journal of Medicinal Chemistry|March 3, 2006
Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigationsGiorgia Pastorin, Tatiana Da Ros, Chiara Bolcato, et al.
Journal of Medicinal Chemistry|December 1, 2007
Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key studyErika Morizzo, Francesca Capelli, Ombretta Lenzi, et al.
Pageof 24

Showing results (131-140 of 239) with videos related to

Sort By:
Pageof 24
European Journal of Medicinal Chemistry|December 7, 2015
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptorLucia Squarcialupi, Daniela Catarzi, Flavia Varano, et al.
Molecular Pharmacology|February 24, 2004
Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activationStefania Gessi, Katia Varani, Stefania Merighi, et al.
Molecular Pharmaceutics|February 2, 2012
A novel conjugated agent between dopamine and an A2A adenosine receptor antagonist as a potential anti-Parkinson multitarget approachAlessandro Dalpiaz, Barbara Cacciari, Chiara Beatrice Vicentini, et al.
Bioorganic & Medicinal Chemistry|December 30, 2011
Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonistsPier Giovanni Baraldi, Giulia Saponaro, Mojgan Aghazadeh Tabrizi, et al.
Journal of Medicinal Chemistry|January 7, 2005
Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key studyStefano Moro, Paolo Braiuca, Francesca Deflorian, et al.
Molecular Pharmacology|May 10, 2007
Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cellsStefania Merighi, Annalisa Benini, Prisco Mirandola, et al.
Plos One|June 7, 2013
Pulsed electromagnetic fields increased the anti-inflammatory effect of A₂A and A₃ adenosine receptors in human T/C-28a2 chondrocytes and hFOB 1.19 osteoblastsFabrizio Vincenzi, Martina Targa, Carmen Corciulo, et al.
Bioorganic & Medicinal Chemistry|September 3, 2003
New strategies for the synthesis of A3 adenosine receptor antagonistsPier Giovanni Baraldi, Andrea Bovero, Francesca Fruttarolo, et al.
Journal of Medicinal Chemistry|March 3, 2006
Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigationsGiorgia Pastorin, Tatiana Da Ros, Chiara Bolcato, et al.
Journal of Medicinal Chemistry|December 1, 2007
Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key studyErika Morizzo, Francesca Capelli, Ombretta Lenzi, et al.
Pageof 24